News and Trends 2 Jun 2015
After Failing Phase III, Active Biotech is back to square one
Unfortunately, the Biotech world is not only composed of success stories. Active Biotech, a Swedish company focused on developing treatments for neurodegenerative diseases and cancer. The company, engaged with Ipsen, discontinued a Phase III study and is currently discovering the consequences of this failure the hard way. Active Biotech’s business model, like many small red biotechs, is based on partnering with […]